Clinical Report: Glaucoma Trials Tracker
Overview
This report summarizes active interventional clinical trials related to glaucoma, highlighting various treatment approaches and their objectives. Notable trials include evaluations of brimonidine tartrate, topical insulin, and novel encapsulated cell therapies.
Background
Glaucoma is a leading cause of irreversible blindness worldwide, necessitating ongoing research into effective treatments. Clinical trials play a crucial role in advancing therapeutic options and improving patient outcomes. Understanding the landscape of current trials can inform clinical practice and guide treatment decisions.
Data Highlights
| Trial Name | Phase | Enrollment | Purpose |
|---|---|---|---|
| Brimonidine Tartrate Ophthalmic 0.025% | Phase 4 | 35 | Evaluate effect on conjunctival hyperemia |
| Topical Insulin for Glaucoma | Phase 1 | 52 | Determine safety in optic neuropathies |
| BL1107 Eye Drops vs Timolol | Phase 2 | 228 | Evaluate safety and efficacy in glaucoma |
| NT-501 Encapsulated Cell Therapy | Phase 2 | 30 | Assess visual impairment related to glaucoma |
| iStent Infinite and iDose TR | Phase 4 | 20 | Investigate efficacy for intraocular pressure reduction |
Key Findings
- Brimonidine tartrate 0.025% is being evaluated for its effect on conjunctival hyperemia in patients using netarsudil/latanoprost.
- Topical insulin is undergoing safety assessment in patients with various optic neuropathies.
- BL1107 is compared with timolol for safety and efficacy in primary open-angle glaucoma.
- NT-501 encapsulated cell therapy aims to improve visual outcomes in glaucoma patients.
- The iStent Infinite and iDose TR are being tested as alternatives to filtering surgery for intraocular pressure management.
Clinical Implications
The ongoing trials reflect a diverse approach to glaucoma management, including pharmacological and surgical innovations. Clinicians should stay informed about these developments to optimize treatment strategies and improve patient adherence.
Conclusion
The landscape of glaucoma clinical trials is evolving, with promising new therapies under investigation. Continued research is essential for enhancing treatment efficacy and patient quality of life.
Related Resources & Content
- Glaucoma Physician, Glaucoma Clinical Trials, 2019 -- Evaluation of Safety and Efficacy of Brimonidine Tartrate Ophthalmic Suspension
- Ophthalmology Management, Target Practice, 2009 -- How IOP sets the tone for glaucoma therapy
- Retinal Physician, Clinical Trial Update May 2025 -- Active clinical trials in AMD, DME, RVO, and uveitis
- European Glaucoma Society -- Guidelines and care pathway
- DailyMed - ROCKLATAN- netarsudil and latanoprost ophthalmic solution, 0.02%/0.005%
- Optometric Management — Applying the Most Recent Clinical Data to Improve Glaucoma Treatment
- European Glaucoma Society
- DailyMed - ROCKLATAN- netarsudil and latanoprost ophthalmic solution, 0.02%/0.005% solution/ drops
- Brimonidine Ophthalmic Solution 0.025% for Reduction of Ocular Redness: A Randomized Clinical Trial - PMC
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.